When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Dividend-paying stocks are a traditional defensive play, while healthcare faces fewer trade and economic headwinds than most ...

The current Wall Street sell-off has wiped out billions in market value, hammering tech giants, banks, and airlines while ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

Ignored stocks’ outperform as Big Tech and banks slide ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected ... biotech Halozyme Therapeutics (HALO.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...